Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue
Wang H., Alarcón CN., Liu B., Watson F., Searles S., Lee CK.
Animal Study on Chronic Inflammation, published in Nat Biomed Eng (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Nat Biomed Eng (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 34931077
- PMCID
- PMC9207157
- DOI
- 10.1038/s41551-021-00815-9
- Citations
- 96
Abstract (original English)
Targeting the delivery of therapeutics specifically to diseased tissue enhances their efficacy and decreases their side effects. Here we show that mesenchymal stromal cells with their nuclei removed by density-gradient centrifugation following the genetic modification of the cells for their display of chemoattractant receptors and endothelial-cell-binding molecules are effective vehicles for the targeted delivery of therapeutics. The enucleated cells neither proliferate nor permanently engraft in the host, yet retain the organelles for energy and protein production, undergo integrin-regulated adhesion to inflamed endothelial cells, and actively home to chemokine gradients established by diseased tissues. In mouse models of acute inflammation and of pancreatitis, systemically administered enucleated cells expressing two types of chemokine receptor and an endothelial adhesion molecule enhanced the delivery of an anti-inflammatory cytokine to diseased tissue (with respect to unmodified stromal cells and to exosomes derived from bone-marrow-derived stromal cells), attenuating inflammation and ameliorating disease pathology. Enucleated cells retain most of the cells' functionality, yet acquire the cargo-carrying characteristics of cell-free delivery systems, and hence represent a versatile delivery vehicle and therapeutic system.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level ASystematic ReviewEurope PMC
Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention
Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
- 2026
Int J Nanomedicine1 citations - Level ASystematic ReviewEurope PMC
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Systematic Review on Chronic Inflammation, Immune Modulation, published in Front Oncol (2026) — summary generated from the PubMed abstract.
- 2026
Front Oncol - Level ASystematic ReviewEurope PMC
Trends in peripheral nerve injury research: a bibliometric analysis focused on molecular mechanisms
Systematic Review on Chronic Inflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol